Newsroom
- September 30, 2010
HEALTH CANADA GRANTS VIVIMIND™ A NATURAL HEALTH PRODUCT NUMBER
VIVIMIND™, a natural health product for the brain, is formally authorized for sale in Canada ...
- August 9, 2010
Bellus Health reports results for second quarter ended June 30, 2010
Announcement of new initiatives to reduce burn rate LAVAL, QC, Aug. 9 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") reported today its financial results for the second ...
- May 12, 2010
Annual Meeting of Shareholders - BELLUS Health provides update on corporate and product developments
LAVAL, QC, May 12 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") held its Annual and Special Meeting of Shareholders today. President and Chief Executive Officer Roberto Bellini provided ...
-
BELLUS Health reports results for first quarter ended March 31, 2010
LAVAL, QC, May 12 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") reported today its financial results for the first quarter ended March 31, 2010. ...
-
/R E P E A T -- BELLUS Health Inc. Annual and Special Meeting of Shareholders May 12, 2010/
LAVAL, QC, May 11 /CNW Telbec/ - Dr. Francesco Bellini, Chairman of BELLUS Health Inc. (TSX: BLU), invites all shareholders to attend the Annual and Special Meeting of Shareholders to be held on Wednesday, May 12, 2010 at ...
- May 11, 2010
BELLUS Health Inc. Annual and Special Meeting of Shareholders May 12, 2010
LAVAL, QC, May 11 /CNW Telbec/ - Dr. Francesco Bellini, Chairman of BELLUS Health Inc. (TSX: BLU), invites all shareholders to attend the Annual and Special Meeting of Shareholders to be held on Wednesday, May 12, 2010 at ...
- May 4, 2010
BELLUS Health ends NC-503 diabetes development program following results
LAVAL, QC, May 4 /CNW Telbec/ - BELLUS Health (TSX: BLU) announced today that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept ...
- April 29, 2010
BELLUS Health and Celtic Therapeutics enter agreement for BELLUS' drug candidate KIACTA(TM)
KIACTA(TM) advancing to a confirmatory Phase III clinical trial LAVAL, QC, April 29 /CNW Telbec/ - BELLUS Health (TSX: BLU) and Celtic Therapeutics announced today that they have signed a final agreement pursuant ...
- April 1, 2010
BELLUS Health announces launch of NRM8499 Phase I clinical study for the treatment of Alzheimer's disease
LAVAL, QC, April 1 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") announced today that, on March 30, 2010, the Company initiated a Phase I clinical study for NRM8499, a prodrug of ...
- February 24, 2010
BELLUS Health reports results for fourth quarter and year ended December 31, 2009
LAVAL, QC, Feb. 24 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) (the "Company") reported today its financial results for the fourth quarter and year ended December 31, 2009. All currency figures reported in this press ...
|
